Blow For CureVac As COVID-19 Vaccine Hits 47% Efficacy

Second Interim Readout Disappoints

 
• By Andrew McConaghie
  
TUEBINGEN, GERMANY - NOVEMBER 21: (BILD ZEITUNG OUT) the Logo of Curevac is seen on a sign in front of the CUREVAC building on November 21, 2020 in Tuebingen, Germany.
The results are short of the pre-specified success criteria, and far behind the spectacular 90% plus achieved by Pfizer and Moderna's vaccines. (DeFodi Images/Getty Images)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip